Initiates Coverage on Vascular Biogenics (NASDAQ:VBLT) began coverage on shares of Vascular Biogenics (NASDAQ:VBLTGet Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 29th. Chardan Capital began coverage on Vascular Biogenics in a research report on Thursday, April 28th. They set a “buy” rating and a $5.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Based on data from, the stock presently has an average rating of “Buy” and an average target price of $5.05.

Shares of Vascular Biogenics stock opened at $1.35 on Friday. The firm has a market capitalization of $93.60 million, a PE ratio of -3.00 and a beta of 1.09. The business’s 50-day moving average price is $1.53 and its 200-day moving average price is $1.73. Vascular Biogenics has a 12 month low of $1.10 and a 12 month high of $3.04.

Vascular Biogenics (NASDAQ:VBLTGet Rating) last announced its quarterly earnings data on Wednesday, March 23rd. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative net margin of 3,895.83% and a negative return on equity of 63.08%. During the same quarter last year, the company posted ($0.15) earnings per share. On average, analysts expect that Vascular Biogenics will post -0.47 EPS for the current year.

Large investors have recently made changes to their positions in the business. Two Sigma Advisers LP purchased a new position in Vascular Biogenics during the third quarter valued at $30,000. Spectrum Planning & Advisory Services Inc. purchased a new position in Vascular Biogenics during the fourth quarter valued at $32,000. Goldman Sachs Group Inc. raised its stake in Vascular Biogenics by 44.1% during the second quarter. Goldman Sachs Group Inc. now owns 16,556 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 5,069 shares during the last quarter. Jane Street Group LLC purchased a new position in Vascular Biogenics during the third quarter valued at $42,000. Finally, Envestnet Asset Management Inc. purchased a new position in Vascular Biogenics during the first quarter valued at $64,000. Institutional investors and hedge funds own 26.15% of the company’s stock.

Vascular Biogenics Company Profile (Get Rating)

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications.

Further Reading

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.